TECON(002100)2024-04-29 12:27Financial Performance - The company's operating revenue for Q1 2024 was ¥3,776,851,559.41, a decrease of 2.93% compared to ¥3,890,843,979.48 in the same period last year[10] - Net profit attributable to shareholders was ¥54,063,760.85, a significant increase of 478.54% from a loss of ¥14,282,251.76 in the previous year[10] - The net profit after deducting non-recurring gains and losses was ¥56,677,250.28, up 514.12% from a loss of ¥13,686,317.97 in the same period last year[10] - The company reported a total comprehensive income of ¥7,566,038.59, compared to -¥7,300,826.24 in the previous period[46] - Basic and diluted earnings per share for the current period are both ¥0.04, compared to -¥0.01 in the previous period[46] - Net profit for the quarter reached ¥60.18 million, a significant recovery from a net loss of ¥17.15 million in the same period last year[52] Cash Flow and Liquidity - The company's cash flow from operating activities showed an improvement, with a net outflow of ¥333,850,669.38, a 36.26% reduction from ¥523,750,573.77 in the previous year[10] - The total cash inflow from operating activities for the current period was approximately ¥3.54 billion, a decrease from ¥3.59 billion in the previous period, reflecting a decline of about 1.1%[33] - The cash received from sales of goods and services was approximately ¥3.53 billion, down from ¥3.57 billion in the previous period, indicating a decrease of about 1.2%[33] - The company's cash and cash equivalents at the end of the period amounted to approximately ¥2.68 billion, a decrease from ¥2.82 billion at the beginning of the period, representing a decline of about 4.9%[40] - The net cash flow from operating activities is -¥333,850,669.38, an improvement from -¥523,750,573.77 in the previous period[47] - Cash and cash equivalents at the end of the period amount to ¥2,548,274,731.17, down from ¥3,802,570,554.95 at the beginning of the period[47] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥17,166,609,324.11, representing a 2.48% increase from ¥16,751,659,614.41 at the end of the previous year[11] - Total liabilities amount to ¥9,227,027,848.72, up from ¥8,836,902,688.33, representing an increase of about 4.4%[46] - Long-term borrowings increased to ¥1,560,100,974.71 from ¥1,225,360,197.17, indicating a growth of approximately 27.3%[46] - The total liabilities decreased to approximately ¥12.66 billion from ¥12.93 billion, indicating a decline of about 2.1%[51] - The company's total equity is reported at ¥7,939,581,475.39, compared to ¥7,914,756,926.08 in the previous period, showing a slight increase[46] - The total equity attributable to shareholders increased to approximately ¥4.5 billion, reflecting a positive trend in shareholder value[52] Shareholder Information - The company had a total of 57,682 common shareholders at the end of the reporting period[19] - The total number of shareholders holding more than 5% of shares was reported, with the largest shareholder holding approximately 294.58 million shares, representing about 21.59% of total shares[30] - The top ten shareholders collectively held approximately 1.32 billion shares, accounting for about 98.56% of the total share capital[30] Research and Development - Research and development expenses increased by 65.51% to ¥66,463,953.07, reflecting higher investment in R&D compared to ¥40,156,984.48 in the same period last year[19] - Research and development expenses increased to ¥66.46 million, up from ¥40.16 million, representing a growth of approximately 65%[52] Other Income and Expenses - The company reported a significant increase in other income, which amounted to ¥10,963,408.01, up 31.37% from ¥8,345,527.01 in the previous year[19] - The company reported a decrease in financial expenses to ¥41.54 million from ¥53.76 million, a reduction of about 22.6%[52] Strategic Initiatives - The company has not disclosed any new product developments or market expansion strategies in the current report[28] - The company plans to expand its market presence and invest in new product development to drive future growth[54] - The company is focusing on enhancing its data resources and technology capabilities as part of its strategic initiatives[54] Accounts Receivable and Prepayments - Accounts receivable rose by 62.81% to ¥685,629,062.17, primarily due to increased sales on credit in the pharmaceutical and feed businesses[19] - The accounts receivable increased to approximately ¥685.63 million from ¥421.13 million, showing a significant increase of about 62.8%[40] - The prepayments increased to approximately ¥484.52 million from ¥386.57 million, reflecting an increase of about 25.3%[40]